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Summary Statement 
Cataract surgery combined with intravitreal bevacizumab for patients with diabetic 
retinopathy appears to be an effective and safe treatment in the short term at least.  




Purpose: To evaluate the clinical effectiveness of intravitreal bevacizumab injection 2 
(IVB) combined with cataract surgery in the treatment of patients with cataract and 3 
coexisting diabetic retinopathy (DR).  4 
Methods: Pertinent comparative studies were identified through systemic searches 5 
of PubMed, EMBASE and the Cochrane Controlled Trials Register up to March 1, 2016. 6 
Outcome measures included corrected distance vision acuity (CDVA), central macular 7 
thickness (CMT) and progression of DR and maculopathy. A meta-analysis was 8 
performed by using RevMan (Cochrane Collaboration, Oxford, UK). 9 
Results: Six studies describing a total of 283 eyes were identified. The meta-analysis 10 
results showed that CDVA measured at 1 and 3 months after cataract surgery was 11 
significantly better in the IVB groups than in the control groups (P<0.00001 and 12 
P=0.01), while the CDVA at 6 months did not vary significantly between the two 13 
groups (P=0.24). Similarly, the CMT at 1, 3 and 6 months after surgery was 14 
significantly thinner in the IVB groups than in the control groups (P=0.01, P=0.0004 15 
and P=0.01, respectively). At 6 months, the progression of postoperative DR and 16 
maculopathy occurred more frequently in the control group than the IVB group 17 
(P=0.0001 and P<0.0001, respectively).  18 
Conclusion: Our meta-analysis indicates that cataract surgery combined with IVB 19 
appears to be an effective treatment in patients with coexisting DR in the short-term 20 
(up to 6 months). More randomized, prospective and large sample sized trials are 21 
needed to evaluate the long-term effects of IVB at the time of cataract surgery in 22 
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Diabetic retinopathy (DR) is common eye disease secondary to structural changes at 2 
the capillary endothelium, leading to loss of integrity of the blood-retinal barrier. 3 
Hyperglycaemia directly impacts the endothelium causing increased vascular 4 
permeability, microaneurysms, capillary occlusions, haemorrhages, exudation, and 5 
the accumulation of extracellular fluid and proteins within the macula. Advanced 6 
proliferative DR can cause vitreous haemorrhaging and tractional retinal 7 
detachments resulting in severe visual loss.1 Diabetic macular edema (DME) is a 8 
frequent manifestation of DR that causes central visual loss.2-4  9 
Apart from the direct occlusive and DME changes to the retina in diabetes, an 10 
important cause of visual loss in patients with diabetes is the acceleration of 11 
cataracts.5 Hence, patients with diabetes have a higher prevalence of cataract than 12 
the normal population6 and patients with pre-existing DR have worse prognosis for 13 
surgical outcomes.7-9 It remains controversial as to the optimal timing of cataract 14 
surgery in patients with DR due to reports of progression of DR and an exacerbation 15 
of DME following cataract surgery.  16 
A study by Kim et al.10 reported that approximately 22% of patients with diabetes 17 
develop increases in central retinal thickness (CMT) after uncomplicated 18 
phacoemulsification, and they suggested that the presence of clinically significant 19 
macular oedema (CSMO) is a strong risk factor for subsequent macular thickening 20 
after cataract surgery.  21 
 7 
It has been well acknowledged that vascular endothelial growth factor (VEGF) plays a 1 
key role in promoting new vessel growth and increases vascular permeability in the 2 
eyes of patients with diabetes.11 Patel et al.12 reported that in patients with DR, the 3 
levels of VEGF165 and other cytokines in the aqueous humour peaked at day 1 and 4 
normalised at 1 month following cataract surgery. Funatsu et al.8 also suggested that 5 
high VEGF levels in the aqueous humour predicted a significant risk for a 6 
post-operative exacerbation of macular oedema following phacoemulsification in 7 
patients with non-proliferative DR. Therefore, anti-VEGF therapy performed at the 8 
time of cataract surgery appears to be a reasonable intervention for preventing 9 
complications related to the progression of DR. 10 
Bevacizumab (Avastin, Genetech, Inc., San Francisco, CA) is a humanised monoclonal 11 
antibody that inhibits all isoforms of VEGF-A. To date, several comparative 12 
studies13-19 have been performed to assess the efficacy of intravitreal bevacizumab 13 
at the time of cataract surgery in order to prevent the postoperative progression of 14 
DR. However, the results from these studies were inconsistent. Furthermore, the 15 
scientific evidence of a single study can be limited by a small sample size, different 16 
populations, follow-up period, and surgical technique. Therefore, the aim of this 17 
study was to undertake a meta-analysis to evaluate the clinical effectiveness of 18 
intravitreal bevacizumab, injected at the time of cataract surgery in patients with 19 




Databases and Search Strategy 1 
Reports of clinical trials comparing cataract surgery with and without simultaneous 2 
IVB therapy in patients with DME were identified through a systematic search of 3 
PubMed, EMBASE and the Cochrane Controlled Trials Register up to March 1, 2016. 4 
A comprehensive search was conducted using the following terms: diabetic macular 5 
oedema, DMO, diabetic macular edema, DME, anti-VEGF therapy, bevacizumab, 6 
avastin, diabetic maculopathy and cataract. No language restriction was used. 7 
Citations initially selected by a systematic search were first retrieved as title and/or 8 
abstract and screened independently by two reviewers. Potentially relevant reports 9 
were retrieved as complete manuscripts and assessed for compliance to the 10 
inclusion and exclusion criteria. The reference lists of original reports and review 11 
articles retrieved by the search were reviewed for additional studies not included in 12 
the initial search. 13 
Inclusion and Exclusion Criteria 14 
The following selection criteria were used to identify published studies for inclusion 15 
in this meta-analysis: (i) randomised controlled studies (RCTs) or cohort studies; (ii) 16 
patients aged more than 18 years, with cataract and pre-existing DR, who were 17 
scheduled for cataract surgery alone (control group) or combined with an intravitreal 18 
injection of bevacizumab at the end of surgery (IVB group); (iii) all patients received 19 
similar routine medication pre- and post-operatively, and no further IBV were 20 
performed for patients of both groups during the follow-up times and (iv) pre- and 21 
post-operative corrected distance visual acuity (CDVA) or central macular thickness 22 
 9 
(CMT) being measured, and a follow-up period of at least 3 months. Exclusion 1 
criteria were studies including patients with a history of ocular surgery, ocular 2 
inflammation, the presence of other ocular diseases, and intraoperative 3 
complications such as posterior capsule rupture and severe iris damage. Abstracts 4 
from conferences, full texts without raw data available for retrieval, letters, and 5 
review articles were excluded. Where multiple publications based on the same 6 
cohort were identified, the report with the largest number of patients was used. 7 
Data Extraction 8 
Two reviewers independently extracted data and assessed the methodological 9 
quality of the trials. Results were compared and any discrepancies resolved by 10 
discussion involving a third reviewer when necessary. The recorded characteristics of 11 
the studies included: name of first author, year of publication, geographical location 12 
of the study, major inclusion and exclusion criteria, number of eyes, mean age and 13 
gender of patients in each group, follow-up periods and the proportion of 14 
withdrawals. 15 
Assessment of Bias Risk  16 
Two authors independently assessed the studies using the Cochrane Collaboration’s 17 
“Risk of Bias” tool from the Cochrane Handbook for Systematic Reviews of 18 
Intervention.20 The criteria used for this were random sequence generation 19 
(selection bias); allocation concealment (selection bias); blinding of participants and 20 
personnel (performance bias); blinding of outcome assessments (detection bias); 21 
 10 
incomplete outcome data (attrition bias); selective reporting (reporting bias); and 1 
other sources of bias.  2 
Outcome Measures 3 
The main outcome measures were the mean change in CDVA from baseline and the 4 
mean change in CMT from baseline at 1, 3 and 6 months. Progression of 5 
post-operative DR and diabetic maculopathy after surgery were also assessed as 6 
secondary outcome parameters. DR was considered to have progressed when (i) a 7 
patient with pre-existing DR developed a higher grade of retinopathy, with or without 8 
progression within the macula (e.g., mild non-proliferative DR progressed to 9 
moderate non-proliferative DR or more), or (ii) a patient with or without 10 
maculopathy developed CSMO or an increase in retinal thickening or hard exudation 11 
associated with retinal thickening from baseline levels.17 12 
Statistical Analysis 13 
Original data were obtained from the articles as far as possible; data that could not 14 
be obtained were calculated if possible (e.g., when standard deviations (SD) were not 15 
available, they were calculated using the sample sizes and standard error [SE]). When 16 
neither the SD nor SE of end point measurements were available, the baseline SD 17 
was used as an estimate of the SD of any time point post-operatively. When only the 18 
P-value for the difference between the two groups was reported, the SD was 19 
calculated according to the P-value and the sample sizes.20 20 
All statistical analyses were performed using RevMan software (version 5.2; Cochrane 21 
 11 
Collaboration, Oxford, UK). A pooled risk ratio (RR) with the 95% confidence interval 1 
(CI) was calculated for dichotomous outcomes. For the continuous outcomes, the 2 
weighted mean difference (WMD) and their 95% confidence interval (CI) were 3 
calculated. Statistical heterogeneity was tested using the chi-square and I2 statistic. 4 
Heterogeneity was tentatively graded as low, moderate and high with an I2 statistic of 5 
<25%, approximately 50% and >75% respectively.21 Considering the different clinical 6 
characteristics among study groups (e.g. severity of DMO; difference of pre-operative 7 
CDVA, etc) and the variation in sample sizes, the random effects model was used to 8 
pool the data. A sensitivity analysis was performed by excluding non-randomised 9 
control trials or studies including patients without DME. A P-value less than 0.05 was 10 
considered statistically significant. Potential publication bias was examined using a 11 
funnel plot.22 12 
 13 
RESULTS 14 
Identification and Selection Studies 15 
The selection of studies is summarised in Figure 1. A total of 55 articles were 16 
identified, out of which 48 articles were excluded. Of the seven publications that 17 
initially were considered potentially relevant, one was excluded due to a lack of 18 
suitable data for performing the meta-analysis.15 Thus, a total of six studies (five RCTs 19 
and one cohort study) were included in the final meta-analysis.13, 14, 16-19  20 
Study Characteristics and Risk of Bias 21 
 12 
The characteristics and quality assessment of the six studies are summarised in 1 
Tables 1. Overall, 283 eyes (142 assigned to the IVB group and 141 assigned to the 2 
control group) were pooled from the six studies, with sample sizes varying from 26 to 3 
68 across studies. The mean patient age ranged from 60 to 69 years, and 53% were 4 
men. The duration of follow-up ranged from 3 to 6 months. There was no significant 5 
difference between groups in duration of disease and degree of retinopathy before 6 
surgery. All five RCTs13, 14, 15-19 employed appropriate methods of randomisation, and 7 
four RCTs13, 14, 15, 19 reported using more than one blinding method (surgeon, 8 
examiner or patient masked). The risk of bias for all studies is shown in Figure 2.  9 
Central Macular Thickness 10 
The values of CMT at baseline were obtained from all studies except for cheema et 11 
al.17 The combined results showed that there was no significant difference in the 12 
pre-operative CMT between the two groups [five studies (215 eyes)13, 14, 16, 18, 19; 13 
WMD = -1.62; 95% CI -13.29 to 10.05; P=0.79; Figure 3A]. After surgery, the mean 14 
CMT was significantly thinner in the IVB group than the control group at 1 month 15 
[five studies (257 eyes)13, 14, 16, 17, 19 ; WMD = -59.23; 95% CI -104.13 to –14.32; P=0.01; 16 
Fig. 3B], 3 months [six studies (283 eyes)13, 14, 16-19; WMD = -45.83; 95% CI -71.2 to 17 
-20.46; P=0.0004; Fig. 3C] and 6 months [four studies (260 eyes)13, 14, 17, 18; WMD = 18 
-42.7; 95% CI -76.37 to -20.46; P=0.01; Fig. 3D], respectively. A sensitivity analysis 19 
was performed to examine the effect of excluding the cohort study by Chen et al.,19 20 
but this did not alter the results at 1 month (WMD = -46.14; 95% CI -96.17 to 3.90; 21 
P=0.04) and 3 months (WMD = -42.02; 95% CI -69.63 to -14.41; P=0.003). Also, the 22 
 13 
results showed the same trend after excluding the study by Fard et al.14 which 1 
included the patients without DME at 3 months (WMD = -38.71; 95% CI -72.51 to 2 
-4.92; P=0.02) and 6 months (WMD = -60.50; 95% CI -110.72 to -10.29; P=0.02), 3 
except for 1 month (WMD = -47.69; 95% CI -101.02 to 5.46; P=0.08). 4 
Corrected Distance Visual Acuity 5 
The combined results showed that there was no significant difference in the 6 
pre-operative CDVA between the two groups [six studies (283 eyes)13, 14, 16-19; WMD = 7 
-0.01; 95% CI -0.04 to 0.02; P=0.45; Fig. 4A]. After surgery, the mean CDVA was better 8 
in the IVB group than the control group at 1 month [five studies (257 eyes)13, 14, 16, 17, 9 
19; WMD = -0.18; 95% CI -0.25 to -0.12; P<0.00001; Fig. 4B] and 3 months [six studies 10 
(283 eyes)13, 14, 16-19; WMD = -0.08; 95% CI -0.15 to -0.02; P=0.01; Fig. 4C]. However, 11 
no difference was found between the two groups at 6 months [four studies (260 12 
eyes)13, 14, 17, 18; WMD = -0.05; 95% CI -0.15 to 0.04; P=0.24; Fig. 4D]. A sensitivity 13 
analysis was performed to examine the effect of excluding the cohort study by Chen 14 
et al.,19 but this did not alter the results at 1 month (WMD = -0.18; 95 % CI -0.25 to 15 
-0.11; P<0.0001) and 3 months (WMD = -0.08; 95 % CI -0.14 to -0.01; P=0.02). Also, 16 
the results showed the same trend after excluding the study by Fard et al.14 at 1 17 
month (WMD = -0.14; 95% CI -0.22 to -0.05; P=0.002), 3 months (WMD = -0.12; 95% 18 
CI -0.20 to -0.03; P=0.008) and 6 months (WMD = -0.09; 95% CI -0.25 to 0.06; 19 
P=0.24). 20 
Secondary Outcomes 21 
 14 
At 6 months after surgery, the rate of progression of DR and maculopathy in the IVB 1 
group was 9.7% (14/144 eyes) and 6.5% (4/62 eyes), and in the control group was 2 
39.5% (45/114 eyes) and 50.8% (32/63 eyes), respectively. The pooled RRs comparing 3 
the proportion of patients with progression of DR and diabetic maculopathy at 6 4 
months after surgery were in favour of the IVB group. Examination of the forest plot 5 
revealed that progression of post-operative DR [four studies (228 eyes)13, 14, 16, 17; RR = 6 
0.33; 95% CI 0.19 to 0.58] and maculopathy [two studies (125 eyes)13, 17; RR = 0.18; 7 
95% CI 0.09 to 0.37] occurred more frequently in the control group compared to the 8 
IVB group. The difference between groups was statistically significant (P=0.0001 and 9 
P<0.0001; respectively), with no heterogeneity identified (Figures 5A and 5B).  10 
Adverse Effects 11 
No severe ocular or systemic adverse events related to IVB during the follow-up 12 
periods were reported in all six studies.  13 
Publication Bias 14 
Publication bias was assessed for all pooled WMDs with confidence intervals and is 15 
shown as funnel plots in Figure 6. No evidence of publication bias was found. 16 
 17 
DISCUSSION 18 
Our meta-analysis, which included 6 studies revealed that the CDVA measured at 1 19 
and 3 months following cataract surgery was significantly better in the IVB group 20 
compared with the control group. However the difference at 6 months was not 21 
 15 
statistically significant. The CMT at 1, 3 and 6 months after surgery was significantly 1 
lower in the IVB group than in the control group and the progression of DR and 2 
maculopathy occurred less frequently in the IVB group compared to the control 3 
group. 4 
The rate of progression of DR following cataract surgery in the general diabetes 5 
population ranges from 20% to 40%.23-26 Mittra et al.25 found that in 150 eyes 6 
undergoing phacoemulsification cataract surgery, DR progression was observed in 37 7 
eyes (25%) with 6 to 10 months of follow-up. They also reported that 8 
non-proliferative and proliferative DR and surgical inexperience resulted in an 9 
increased rate of retinopathy progression.  10 
The presence of DR before surgery is also an important risk factor for an increase in 11 
macular thickness after cataract surgery which can lead to a suboptimal visual 12 
outcome.27 In the present study, four of the six included studies13, 14, 16, 17 have 13 
reported the rate of progression of post-operative DR and maculopathy, and the 14 
results of meta-analysis showed that these progressions occurred more frequently in 15 
the control group than IVB group.  16 
However, the rate of DR progression after cataract surgery is influenced by multiple 17 
variables and in particular worse outcomes are related to more advanced diabetic 18 
eye disease and poor glycaemic control.28, 29 Moreover, the trauma related to 19 
surgery may play an important pro-inflammatory role, as for instance, it has been 20 
documented that the longer the duration of surgery and the less experienced the 21 
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surgeon, the greater the risk of progression of DR.30 Therefore a large randomised 1 
controlled trial with strict baseline matching is recommended to evaluate the full 2 
effect of IVB therapy in a diabetic population undergoing cataract surgery. 3 
Diabetic patients with preexisting DME are also at increased risk of worsening edema 4 
(i.e., macular edema increase and vision loss) following cataract surgery.4 Our 5 
subgroup analyses confirmed the usefulness of prophylactic IBV for improving 6 
surgical visual outcomes and diminishing CMT in patients with or without DME 7 
before cataract surgery. Although the results are positive, a series of questions such 8 
as edema recurrence rate or the most appropriate subsequent therapies are worth 9 
further investigating. 10 
It is often difficult to distinguish between DME and pseudophakic cystoid macular 11 
edema (PCME) after cataract surgery in diabetic patients.31 However, the PCME is 12 
usually associated with complicated cataract extractions and resolves spontaneously 13 
in the majority of cases. All cataract surgeries included in the current meta-analysis 14 
were uncomplicated. In addition, optical coherence tomography (OCT) as a suitable 15 
tool to differentiate ME attributed to diabetes and PCME, was used in all including 16 
studies.32 17 
Intravitreal triamcinolone33 or dexamethasone intravitreal implant34 has been shown 18 
to be effective for macular edema at the time of cataract surgery but has been 19 
associated with complications such as increased intraocular pressure. Although the 20 
exact pathogenesis of macular edema and its progression after cataract surgery is 21 
 17 
not well understood, an imbalance between endothelial growth factors, cytokines, 1 
and inhibitory factors is likely to be involved. VEGF is an important factor in the 2 
development of macular oedema because it leads to a breakdown of the inner 3 
blood-retinal barrier and leakage of intravascular fluid from abnormal retinal 4 
capillaries, within the intra-retinal layers of the macula.35, 36 Further, studies have 5 
reported a correlation between increased pre-operative levels of VEGF and 6 
interleukin-6 in the aqueous and a deterioration in macular edema.8, 12, 37 It is 7 
hypothesised that anti-VEGF therapy, would help to prevent the development of 8 
macular edema following cataract surgery in patients with diabetes. The results of 9 
our meta-analysis suggest that patients with DR who undergo combined cataract 10 
surgery and IVB have better visual acuity (albeit in the short term), lower CMT and 11 
reduced progression of DR and maculopathy post-operatively compared to controls. 12 
Normal physiological function requires low levels of systemic VEGF activity. 13 
Suppression of this baseline activity can cause hypertension, thromboembolic events, 14 
bowel perforation, and delayed wound healing.38, 39 Thus, there is a theoretical risk 15 
with the application of intravitreal anti-VEGF drugs that it may influence normal 16 
physiological functions resulting in systemic complications. However, no systemic or 17 
ocular adverse events that could be related to the injection itself or the medication 18 
used was observed in all studies included in this meta-analysis. 19 
This work has some limitations. First, we did not search for unpublished studies or 20 
conference abstracts. Second, the follow-up period was short in this meta-analysis (6 21 
 18 
months). Third, the dose of bevacizumab (1.25mg) used in all studies is the dose 1 
most commonly used in clinical practice. Because no dose-ranging study has been 2 
done, the ideal intravitreal concentration remains to be determined. 3 
As far as the authors are aware, this is the first systematic review to consolidate the 4 
current knowledge of published data regarding the use of bevacizumab in patients 5 
with DR who are undergoing cataract surgery. Our data suggests that cataract 6 
surgery combined with IVB for patients with DR appears to be an effective and safe 7 
treatment in the short term at least. Therefore, more randomised, prospective and 8 
large sample sized studies are needed to evaluate the long-term effects of 9 
intravitreal anti-VEGF therapy at the time of cataract surgery in patients with DR.10 
 19 
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Figure legends 
Figure 1. Flowchart of literature search and study selection.  
Figure 2. Assessment of risk of bias in included studies. (A) Risk of bias summary: 
review authors’ judgments about each risk of bias item for each included study; (B) 
Risk of bias graph: review authors’ judgments about each risk of bias item presented 
as percentages across all included studies. +: low risk of bias. ?: unclear risk of bias. 
Figure 3. Forest plot comparison of central macular thickness after cataract surgery 
with and without intravitreal bevacizumab injection: (A) baseline, (B) 1 month, (B) 3 
months, and (D) 6 months.  
Figure 4. Forest plot comparison of best-corrected visual acuity after cataract 
surgery with and without intravitreal bevacizumab injection: (A) baseline, (B) 1 
month, (C) 3 months, and (D) 6 months.  
Figure 5. Forest plot comparison of the proportion of patients in (A) diabetic 
retinopathy progression and (B) maculopathy progression at 6 months after cataract 
surgery with and without intravitreal bevacizumab injection. 
Figure 6. Funnel plot with respect to best-corrected visual acuity after surgery. No 
publication bias was observed. 
 
